[40] Aguiar, M. and Nico Stollenwerk (2020). The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study. Vaccines, 8(4): 674.

[39] Aguiar, M., Ortuondo, E.M., Bidaurrazaga Van-Dierdonck, J. et al. (2020). Modelling COVID 19 in the Basque Country from introduction to control measure response. Scientific Reports, 10: 17306.

[38] Aguiar, M., Stollenwerk, N. (2020). Condition-specific mortality risk can explain differences in COVID-19 case fatality ratios around the globe. Public Health, 188: 18–20.

[37] Aguiar, M., Bidaurrazaga Van-Dierdonck, J., Stollenwerk N. (2020). Reproduction ratio and growth rates: Measures for an unfolding pandemic. PLoS ONE, 15(7): e0236620.

[36] Aguiar, M., & Stollenwerk, N. (2020). SHAR and effective SIR models: from dengue fever toy models to a COVID-19 fully parametrized SHARUCD framework. Communication in Biomathematical Sciences, 3(1): 60-89.

[35] Halstead, S.B., Katzelnick, L.C., Russell, P.K., Markoff, L.,Aguiar, M., Dans, L.R., Dans, A.L. (2020).  Ethics of a partially effective dengue vaccine: Lessons from the Philippines. Vaccine, 38(35): 5572–5576.

[34] Rashkov, P., Venturino, V., Aguiar, M., Stollenwerk, N., & Kooi, B.W. (2019). On the role of vector modeling in a minimalistic epidemic model. Mathematical Biosciences and Engineering, 6(5): 4314-4338.

[33] Skwara, U., Mateus, L., Filipe, R., Rocha, F., Aguiar, M. and Stollenwerk, N. (2018). Superdiffusion and epidemiological spreading. Ecological Complexity, 36: 168-183.